Across TCGA pan-cancer cohorts, TRAJ22 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TRAJ22’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where TRAJ22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRAJ22 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

BRCA, LUSC, and KIRC are the cancer types where TRAJ22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRAJ22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	+0.265	.019	4	view →
LUSC	All	II,III,IV	+0.283	.026	2	view →
KIRC	All	II,III,IV	+0.179	.021	1	view →
THCA	All	All	−0.179	.015	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TRAJ22 RNA expression & survival · all TRAJ22 data types